Floatz Rating
B57/100
Confidence
Indicative
Sponsor
University of Alabama at Birmingham
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01383759CT.gov Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Amyloidosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bortezomib (this asset) | University of Alabama at Birmingham | P2 | B · 57 |
| Acoramidis | Bayer | P4 | BBB |
| Dexasone | Ascentage Pharma Group Inc. | P3 | BB |
| Tafamidis | Pfizer | P4 | BB |
| Empagliflozin | Columbia University | P4 | BB |
| Cyclophosphamide | University of Alabama at Birmingham | P2 | BB |
| Lenalidomide | Ascentage Pharma Group Inc. | P3 | BB |
| Enavogliflozin | Seoul St. Mary's Hospital | P4 | BB |
| Evuzamitide | National Institute of Allergy and Infectious Diseases (NIAID) | P2 | BB |
+26 more in the Amyloidosis cohort
Other indications for Bortezomib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | BBB · 73 |
| Follicular Lymphoma | — | P2 | BB · 71 |
| Waldenstrom Macroglobulinemia | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bortezomib in Amyloidosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bortezomib-amyloidosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →